CLL Support

📣 Last chance to tell us about your experience 📣

If you are living with CLL/SLL in the UK, or supporting someone with CLL/SLL, please take 10-15 mins to complete the relevant survey.

Your responses help us understand what life is really like and what needs to change.

Partners, carers, family and friends often go unheard - but your experience matters too.

Click here if you have CLL/SLL:
https://opinions.research-interactive.com/survey/selfserve/1c3c/260101?list=5

Click here if you support someone who has CLL/SLL:
https://opinions.research-interactive.com/survey/selfserve/1c3c/260400?list=5

The recordings from our recent Leeds Conference are now available to watch on our YouTube channel.

CLL Support Leeds Conference 2026 Del dine videoer med venner, familie og verden

For more information, or to take part and release your inner 🕺💃 email [email protected]

The Scottish Medicines Consortium (SMC) approved an additional treatment for CLL earlier this month, on 13th April. The combination therapy of acalabrutinib and venetoclax with or without obinutuzumab was approved for first line therapy in previously untreated patients with CLL. The treatment is available for restricted use on the NHS via the NHS Scotland Patient Access Scheme (PAS)

Further information is available via the SMC website: https://scottishmedicines.org.uk/medicines-advice/acalabrutinib-calquence-abb-smc2893/


🏴󠁧󠁢󠁳󠁣󠁴󠁿

📣 Bookings are now open for our free to attend Birmingham Conference.

Our keynote speaker is Dr Helen Parry, Honorary Consultant Haematologist at The Queen Elizabeth Hospital, Birmingham. Helen will be joined by Lewis Oxley, Specialist Dietician - Haematology and Oncology.

Invitations to book have been emailed to everyone on our mailing list. If you would like to attend the conference but haven't joined our mailing list you can do so here: https://cllsupport.org.uk/newsletter-sign-up/

You will receive an invitation to book shortly afterwards.